Antibody-drug conjugates (ADCs) have advantages including target specificity, wide therapeutic index and prolonged circulation half-life. A key limitation of ADCs, however, is the large size (∼150 kDa ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results